Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Fabre-Kramer Pharmaceuticals and GlaxoSmithKline have announced that the Food and Drug Administration has issued a not approvable letter for a new drug application for gepirone extended release tablets, submitted for the treatment of adults with major depressive disorder.
Subscribe to our email newsletter
The Food and Drug Administration (FDA) had previously reviewed Phase I through III clinical data involving gepirone extended release (ER). In June 2004, the FDA requested an additional positive short-term trial in order to consider gepirone ER for approval. Subsequently, Fabre-Kramer (FKP) successfully conducted a trial in patients with major depressive disorder to respond to the FDA request for an additional positive pivotal study.
Those results were submitted to the FDA in May 2007. The not approvable letter issued today is based on the FDA review of those additional results along with other newly submitted and previously submitted data.